Résumé
In recent years,great progress has been achieved in the application of immune checkpoint inhibitors (ICI) in tumor immunotherapy.However,a variety of adverse reactions induced by ICI have been reported.Despite the high overall incidence of adverse reactions caused by ICI,some adverse reactions,such as immune-related pancreatitis,are rare in clinical practice.In this paper,a case of immune-related pancreatitis after treatment of advanced gastric cancer with nivolumab was identified.We analyzed the cause,treatment,incidence,and risk factors of the adverse reaction,aiming to improve the clinical diagnosis,treatment,and safe medication of rare adverse reactions associated with ICI.
Sujets)
Humains , Nivolumab/effets indésirables , Inhibiteurs de points de contrôle immunitaires/effets indésirables , Antinéoplasiques immunologiques/effets indésirables , Pancréatite/traitement médicamenteux , Tumeurs de l'estomacSujets)
Humains , Mâle , Adulte , Jeune adulte , Maladie de Hodgkin/traitement médicamenteux , Antinéoplasiques immunologiques/effets indésirables , Nivolumab/effets indésirables , Néphrite interstitielle/induit chimiquement , Effets secondaires indésirables des médicaments , Antinéoplasiques immunologiques/usage thérapeutique , Nivolumab/usage thérapeutique , Néphrite interstitielle/anatomopathologieRésumé
El melanoma ha experimentado un aumento constante en su tasa de incidencia en las últimas cinco décadas a nivel mundial. El pronóstico del paciente con melanoma se relaciona con el estadio de la enfermedad al momento del diagnóstico, con una sobrevida global media de 6,2 meses en pacientes con melanoma metastásico. El avance en las investigaciones sobre la biología y el comportamiento tumoral permitió el desarrollo de nuevas terapias con distintos mecanismos de acción y mayor eficacia. En esta revisión se abordan las terapias biológicas en melanoma metastásico, su mecanismo de acción y principales resultados en ensayos clínicos. (AU)
Melanoma has experienced a consistent increase in incidence over the past five decades worldwide. The prognosis of patients with melanoma is related to the stage of disease at diagnosis, with a median overall survival of 6.2 months in metastatic melanoma. Progress in research on tumor biology allowed the development of new therapies with different mechanisms of action and greater efficiency. In this review, biologic therapies in metastatic melanoma, its mechanism of action and main results in clinical trials are discussed. (AU)